As an independent family-owned company, DR FALK PHARMA focuses on improving patient outcomes through a dual approach: firstly, through providing high quality education and information for the gastroenterology and hepatology communities (doctors, nurses, patient groups and researchers) and, secondly, by offering effective therapies for IBD and cholestatic liver diseases in the form of Salofalk, Budenofalk and Ursofalk.
Improving outcomes
These are all available in a range of formulations designed specifically to aid patient adherence. Visit the Dr Falk stand to discuss Salofalk granules which have recently been approved for single, daily use in acute ulcerative colitis to help patient adherence to treatment.
